On February 14, 2025, Ono Pharmaceuticals secured FDA approval for vimseltinib, a therapy for tenosynovial giant cell tumor (TGCT), which will be marketed as ROMVIMZA. This approval places Ono in direct competition with another Japanese pharmaceutical company, Daiichi Sankyo, in the TGCT...
Hence then, the article about ono s romvimza approval shakes up tenosynovial giant cell tumors market challenging daiichi sankyo s turalio dominance delveinsight was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Ono's ROMVIMZA Approval Shakes Up Tenosynovial Giant Cell Tumors Market, Challenging Daiichi Sankyo's TURALIO Dominance .. DelveInsight )
Also on site :
- Soul Hitmaker Behind One of the ‘Greatest’ 1974 R&B Chart-Toppers “Let’s Straighten It Out,” Dies at 86
- Hayden Panettiere Appeared ‘Beaten Up’ as Firefighters Transported Her on a Gurney 2 Years Before She Died: Neighbor
- A66 crash: Tributes to five young men and teenagers killed in wrong way collision with Cleveland police car